AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04879641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: Participants are instructed to plan and track in vivo exposures using an exposure diary. Participants are also instructed to reduce safety behaviors, which are overt or covert acts such as avoiding eye contact or rehearsing sentences to prevent a feared outcome.
Study NCT04879641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training
Description: Participants are trained to reduce self-focused and biased attention. Various audio exercises are introduced in which participants learn to intentionally direct the attention away from themselves (i.e., less private self-consciousness), and to be less alert to potentially dangerous external social stimuli (i.e., less public self-consciousness).
Study NCT04879641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring
Description: Participants are instructed to identify and modify dysfunctional and negatively biased assumptions. It includes a thought diary to track negative beliefs in daily routine, alongside with exercises to formulate helpful and adaptive thoughts.
Study NCT04879641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Participants are delivered detailed evidence-based information on SAD with a focus on maintaining processes (e.g., the vicious circle of negative thoughts and emotions, cognitions, and behaviors associated with the maintenance of SAD). Based on the information provided, participants are encouraged to develop an individual model of their social anxiety symptoms.
Study NCT04747093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-ITNK cells
Description: CAR-ITNK cells will be infused over 10-15 minutes on Day 0.
Study NCT04843215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of omentectomy
Description: Experimental group D2 radical gastrectomy with partial omentectomy. Partial omentectomy with preservation of the greater omentum at >3 cm from the gastroepiploic arcade.Control group with total omentectomy.
Study NCT06456528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL0911
Description: QL0911
Study NCT06456528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL0911 plus Placebo
Description: QL0911 plus Placebo
Study NCT06456528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04844684 — intervention group
Intervention type: OTHER
Intervention: Blood and urine collection
Description: Blood sampling urine collections before RYGP and 1 month and 1 year after.
Study NCT05691049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HCC_45
Description: Dosage form: HCC_45 is a resorbable medical device 2 ml non-pyrogenic pre-filled syringe, containing 2 ml of hyaluronic acid for intradermal use.~The principal component of the medical device is Hyaluronic Acid of non-animal origin, produced by bacterial fermentation.
Study NCT06162000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The group that will use the developed software in case studies
Description: In the study, a case study will be conducted with students in the control and intervention groups once a week for four weeks.~Students in the control group will be given printed cases and asked to prepare care plans on ready-made paper templates.~Case preparation activities of the students in the intervention group will be carried out in line with the software planned to be developed. Before the case preparation activities begin, an information/promotional meeting will be held regarding the use of the application planned to be developed. Students will log in to the application with their e-mail addresses and the password they will choose when they first log in. Students will be asked to review the software and questions regarding usage will be answered. Students will record patient data in the cases into KSDE-HBPYS and prepare care plans with the software. At the end of the case studies, a posttest case and Clinical Decision Making Scale will be applied to both groups.
Study NCT05407909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX2001
Description: SYHX2001 tablets, oral
Study NCT06736496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: patients will receive : nalbuphine administered at a dose of 0.2 mg / kg IV bolus dose before induction and intermittent doses of 0.5 mg/kg if MAP and HR greater than 20% of the base line value.
Study NCT06736496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: patients will receive : Dexmedetomidine infusion at rate of 0.5mcg/kg/h initiated 10 min before induction and ketamine iv bolus dose of 0.35 mg/kg and Lidocaine iv bolus dose of 1mg/kg administrated before skin incision.
Study NCT06736314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a removable titanium clip
Description: The removable titanium clip is a new type of titanium clip that offers advantages such as easy operation and convenient disassembly.
Study NCT05470946 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Double balloon enteroscopy
Description: Double balloon enteroscopy (EN-580T, Fujifilm, Japan)
Study NCT04206995 — intervention group
Intervention type: OTHER
Intervention: Solid Phase Microextraction (SPME)
Description: A SPME fibre is held directly above skin cancer, or healthy skin for a period of less than 30 minutes to capture VOCs. No drug will be used. This is to investigate the capability of the technique in capturing VOCs.
Study NCT04206995 — intervention group
Intervention type: OTHER
Intervention: Absorptive patch
Description: An adsorptive patch, covering skin cancer and healthy skin sites will be applied for a period of maximum 30 minutes to capture VOCs. No drug will be used. This is to investigate the capability of the technique in capturing VOCs.
Study NCT06235814 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Molecular Analysis for Thyroid Resection
Description: Protocol for Operative Management based on Molecular Risk Classifier~Patients will have a televisit (i.e. video-visit) with us in 2 weeks once the ThyroSeq molecular analysis results. In that visit, we will discuss the operation the patient will receive, including the risks and benefits of the operation. Operative management will be dictated by the molecular results listed below:~* Low molecular-risk: thyroid lobectomy~* High molecular-risk: total thyroidectomy~* Intermediate molecular-risk: randomization to thyroid lobectomy or total thyroidectomy~Of note, the respective operations for the low and high molecular-risk groups are standard of care.
Study NCT05490173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exosomes derived from mesenchymal stromal cells (MSCs)
Description: Exosomes derived from mesenchymal stromal cells (MSCs) will be administered intranasal in ELBW infants
Study NCT04650282 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lidocaine in SphenoCath device
Description: Participants will receive 2.5 cc of lidocaine 1% solution intranasally via a SphenoCath device into each nares.The portion of the procedure involving this device lasts approximately 30-60 seconds.
Study NCT04650282 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution in SphenoCath device
Description: Participants will receive saline solution via a SphenoCath device into each nares. The portion of the procedure involving this device lasts approximately 30-60 seconds.
Study NCT05495139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver Disease
Description: This study includes 3 phases; screening period, procedural period, and a follow-up period. Following a 2-week screening period, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 2; Day 0). Following a 6-month treatment period, the device is removed, and subjects are followed for 6 months. In total subject participation will last for approximately 12 months.
Study NCT04823611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A:Placebo
Description: Placebo solution
Study NCT04823611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A:AZD8233
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
Study NCT04823611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part B:Placebo
Description: Placebo solution
Study NCT04823611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B:AZD8233
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
Study NCT04823611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part C: Placebo
Description: Placebo solution
Study NCT04823611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part C: AZD8233
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
Study NCT06013592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 0 kcal liquid meal
Description: Flavoured water, given as one meal at one study visit only
Study NCT06013592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 600 kcal liquid meal
Description: Fortisip Compact Vanilla, given as one meal at one study visit only
Study NCT06013592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 900 kcal liquid meal (only for group without obesity)
Description: Fortisip Compact Vanilla, given as one meal at one study visit only
Study NCT06013592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1200 kcal liquid meal
Description: Fortisip Compact Vanilla, given as one meal at one study visit only
Study NCT06013592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1800 kcal liquid meal (only for group with obesity)
Description: Fortisip Compact Vanilla, given as one meal at one study visit only
Study NCT05044689 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire containing questions regarding diet, physical activity, past medical history and life style practices.
Study NCT05044689 — intervention group
Intervention type: DEVICE
Intervention: Bioimpedance/Body Composition Unit
Description: Patients will provide information on body composition through the use of a bioimpedance machine which measures the body mass index, fat and total body water.
Study NCT04763369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa
Description: Cultured stem cells will be injected in the sub-tenon space of eye and patients will be monitored and evaluated for outer retinal thickness, early treatment of diabetic retinopathy study visual acuity, visual field sensitivity, fundus photography, amplitudes of multifocal electroretinogram and implicit times of multifocal electroretinogram at baseline (day 0) and days 30, 60, 90, 180, 270 and 360.
Study NCT04763369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa
Description: Cultured stem cells will be injected in the suprachoroidal space of eye and patients will be monitored and evaluated for outer retinal thickness, early treatment of diabetic retinopathy study visual acuity, visual field sensitivity, fundus photography, amplitudes of multifocal electroretinogram and implicit times of multifocal electroretinogram at baseline (day 0) and days 30, 60, 90, 180, 270 and 360.
Study NCT06351007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional education and psychological intervention
Description: In the two intervention groups, after the delivery of the meal plan, the educational and psychological intervention will begin, with a duration of 5 months. The main objective of the educational program in pre-dialysis patients is to delay the progression of renal damage and in dialysis patients is control of complications. The content of monthly educational sessions will be:~Month 1: proteins (predialysis group), potassium (dialysis group) Month 2: Sodium and fluids (predialysis group), phosphorus (dialysis group) Month 3: Phosphorus (predialysis group), sodium and fluids (dialysis group) Month 4: Potassium (predialysis group), proteins (dialysis group) Month 5: Myths and facts about food (both groups) Simultaneously, group psychological sessions will be carried out, aimed at modifying patient behaviors to increase adherence to diet plan through understanding the patient´s situation, promoting the development of healthy behaviors, barrier identification and goal setting
Study NCT06351007 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The control group (predialysis and dialysis patients) will receive standard nutritional care consisting of dietary prescription with follow-up for questions and adjustment of the meal plan every 2 months.~Based on the nutritional status, biochemical parameters and stage of renal disease, the meal plan will be calculated.~The characteristics of the diet will be as follows:~Calories - 30 kcal/Kg ideal body weight/day Protein - 0.8 g/kg ideal body weight/day (predialysis group) 1.2 kg ideal body weight/day (dialysis group) Carbohydrates - 50-60% of total calorie content Lipids - 30% of total calorie content Sodium \&lt; 2300 mg/day Potassium \&lt; 2000 mg/day Phosphorus \&lt; 1000 mg/day Fluids - Urine output + 500 ml
Study NCT06001996 — intervention group
Intervention type: PROCEDURE
Intervention: Pericapsular nerve group (PENG) block
Description: Pericapsular nerve group (PENG) block: Using an in-plane approach with ultrasonographic imaging, the block needle reaches the fascial plane between the psoas muscle and the superior pubic ramus and local anaesthetic solution is injected.
Study NCT06001996 — intervention group
Intervention type: PROCEDURE
Intervention: Suprainguinal fascia iliaca plane block
Description: Suprainguinal fascia iliaca plane block: The needle entering in plane from the caudal end of the ultrasound probe passes through the m. sartorius and into the musculus iliacus and fascia iliaca reaches. The fascia iliaca is passed with the needle and local anaesthetic solution is injected immediately under the fascia.
Study NCT05948007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Description: 12 training sessions within 6 weeks will be provided. In each training session, participants will have neurofeedback training for five 3-minute training periods.
Study NCT05948007 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-neurofeedback training
Description: The Sham group has the same training dosage as the neurofeedback group.
Study NCT05948007 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain management protocol
Description: The treatment components include sleep psychoeducation, sleep hygiene education, exercise consultation, and cognitive-behavioral pain management, i.e., practice in changing dysfunctional thoughts, setting and working toward behavioral goals, relaxation skills
Study NCT05989698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-mo System
Description: Patients will use C-mo System for a period of 24h, to assess cough characteristics.
Study NCT04490395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engage PA
Description: Engage PA will consist of a 2-session intervention delivered to participants at the medical center or virtual visit by their study therapist, and includes a wearable personal fitness monitor for tracking their daily activity levels throughout.
Study NCT04490395 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual plus (TAU+)
Description: The comparison condition will receive treatment as usual throughout the study, and are given a wearable personal fitness monitor for tracking their daily activity levels throughout the study.
Study NCT05341648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Warm-up: 5 minutes Aerobic Training Treadmill/cycle ergometer Frequency:3 days a week Intensity:40-70% of HR max(Start from 40% than increment to as per patient tolerance) Total Duration:6 weeks. Duration of each session:15-30 mins. Cool-down: 5 minutes
Study NCT05341648 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Home Plan
Description: * Positions to ease breathlessness~* Controlled breathing/Deep breathing\*10 Reps\* TD,s~* Progressive Muscle Relaxation Exercises.~* ROM \& Flexibility Exercises. 3 days a week for 6 weeks.
Study NCT04863079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Pembrolizumab 200 mg IV, Q3W, up to one year or disease progression or intolerance.
Study NCT06304077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forest
Description: Participants in the intervention groups will receive 5 VR training sessions over 10 days in addition to their usual care. Each participant will wear the HMD for 25 minutes in each of this training sessions, whereby he or she will first sit for 5 minutes looking at a forest-landscape. This is followed by 20 minutes of independent exploration of the virtual environment by walking. Depending on the user's gait stability, walking aids (such as walking sticks or rollators) may be used. This phase aims at keeping the participant walking.
Study NCT06304077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urban
Description: Participants in the intervention groups will receive 5 VR training sessions over 10 days in addition to their usual care. Each participant will wear the HMD for 25 minutes in each of this training sessions, whereby he or she will first sit for 5 minutes looking at an urban-landscape. This is followed by 20 minutes of independent exploration of the virtual environment by walking. Depending on the user's gait stability, walking aids (such as walking sticks or rollators) may be used. This phase aims at keeping the participant walking.
Study NCT06304077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rural
Description: Participants in the intervention groups will receive 5 VR training sessions over 10 days in addition to their usual care. Each participant will wear the HMD for 25 minutes in each of this training sessions, whereby he or she will first sit for 5 minutes looking at a rural-landscape. This is followed by 20 minutes of independent exploration of the virtual environment by walking. Depending on the user's gait stability, walking aids (such as walking sticks or rollators) may be used. This phase aims at keeping the participant walking.
Study NCT04618133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early time-restricted eating
Description: Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from 6am to 2pm, with a 1-hour allowance according to their daily routine
Study NCT04618133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late time-restricted eating
Description: Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from noon to 8pm, with a 1-hour allowance according to their daily routine
Study NCT04618133 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Participants will be advised to eat a minimum of 3 meals over the 24-hour cycle, i.e. breakfast from 6am to 9am, lunch from 11am to 2pm, dinner from 6pm to 10pm. Snacks will be allowed between meals
Study NCT05778188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071 (unit strength 10 mg/mL) will be administered by infusion for a dose level of 3, 10, or 20 mg/kg. Planned infusion duration is 10 minutes for all dose levels.
Study NCT05778188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control (commercial sterile saline) will be administered by infusion at a volume matched to RLS-0071 (3, 10, or 20 mg/kg). Planned infusion duration is 10 minutes for all matched dose levels.
Study NCT05091749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: troponin measurement
Study NCT05740085 — intervention group
Intervention type: OTHER
Intervention: Patient information form
Description: Patients will be asked to fill out a patient information form and an osteoporosis awareness form
Study NCT05648058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam ampule
Description: nefopam ampule 50 mg
Study NCT05648058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diphenhydramine ampule
Description: diphenhydramine ampule 10 mg
Study NCT05606250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Percutaneous Neuromodulation
Description: Ultrasound guided percutaneous neuromodulation in femoral nerve. Patients were placed in supine lying with the anterior aspect of the hip uncovered. The intervention consisted of the application of a biphasic square wave electric current, with a frequency of 2 Hz, a phase duration of 250μs, and a maximum tolerable intensity to cause an exacerbated muscle contraction for 15minutes in total
Study NCT04922463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLASOMA
Description: Treatment with cold plasma device
Study NCT06372938 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound measurement
Description: The diagnosis of FGR was made according to the following Delphi criteria . EFW \<3rd percentile or EFW \<10th percentile with Doppler evidence of placental dysfunction (Umbilical artery Doppler (UA) pulsatility index (PI) >95th percentile, absence of umbilical artery end-diastolic flow (UAEDF), or reverse-UAEDF and/or cerebroplacental ratio (CPR) \<5th percentile).